CONTINUUMThe buying trigger
A team needs to understand participation, use patterns or missing context around one product before deciding what to investigate next.
CONTINUUM · INVESTORS
Build on what happens
after the transaction.
The transaction shows what was purchased. Continuum helps reveal what happened next, connecting product identity with personal context and repeated observation.
THE CONTINUUM MODEL
- 01
People participate
Free apps and selected Watch workflows
- 02
Product identity persists
Passports and an organization’s catalog
- 03
Programs focus the question
Defined scope, consent and group review
Personal value supports participation.
Organizational value supports services.
THE OPPORTUNITY
A product can reach a customer.
The learning often stops there.
Across wellness, organizations can see a sale without understanding the routine that followed, what the person noticed or which details are missing. Individuals face the same gap from the other side: keeping a useful record as products and daily circumstances change.
Continuum approaches both needs through shared infrastructure. Cannabis makes product chemistry, batch variation and context especially visible; broad wellness and digestive experience extend the same questions into other parts of everyday life.
WHAT WORKS NOW
A working foundation, with distinct release stages.
| Offering | Current stage | What comes next |
|---|---|---|
| Three free personal apps & Watch | Invitation-based beta; supported device workflows | Refine onboarding and learn from continued use. |
| Partner Core & Product Passports | Free for approved organizations; controlled onboarding | Improve catalog completeness and repeatable onboarding. |
| Cohorts & Insights | Individually scoped organizational services | Deliver useful participant programs and permitted group review. |
| Retail services & owned products | In development, on separate readiness tracks | Validate pilots and finalize product-family details. |
THE COMMERCIAL MODEL
Free entry. Defined organizational services.
The initial commercial priority is a product team that can identify its product and invite participants, but cannot yet describe how use and experience vary beyond the sale. A bounded Cohorts & Insights engagement turns that question into an agreed program and permitted group review.
The first paid deliverable
A defined program: a brief, product references, participant activity and consent, implementation, and a review within agreed reporting limits. Scope and service terms are set individually.
The route to adoption
Free Partner Core provides the product-record starting point. Free personal apps give participants a useful reason to contribute. A separate program invitation establishes what the organization can review.
The model does not depend on giving organizations unrestricted access to personal app histories. CARTA PhytoTherapeutics is a separate regulated adult-use operator for THC-containing products, not owned by Continuum Holdings.
Later options: Retail services, research, licensing and the owned CARTA and PhytoLogic product families follow separate readiness tracks. These are development directions, not established revenue streams.
THE NEXT EVIDENCE
Demonstrate usefulness, then repeatability.
- 01
A reason to return
Can invited participants complete a useful first record and return for follow-up? Onboarding and repeat use are the evidence to establish.
- 02
A practical partner experience
Can an organization prepare a usable catalog and agree a focused program with clear consent and reporting boundaries? A completed onboarding and approved brief are concrete milestones.
- 03
A service that can be delivered again
Can the agreed review answer the scoped question well enough to justify another engagement? Delivery effort, data limitations and partner feedback should guide expansion.
These are milestones to demonstrate, not claims of adoption, retention or revenue.
CONTINUE THE CONVERSATION
Review the company in context.
Request current company materials and product demonstrations. We can discuss the platform, service priorities, owned-product strategy and the milestones behind the next stage of development.
This page describes the company’s strategy and current stage. It is not an offer of securities or a forecast of financial returns.